Radiotherapy for moderate-to-severe Graves' ophthalmopathy: improved outcomes with early treatment

Cancer J. 2003 Nov-Dec;9(6):472-5. doi: 10.1097/00130404-200311000-00007.

Abstract

Purpose: The purpose of this review is to quantify the response to radiotherapy delivered early in the active inflammatory phase of moderate-to-severe Graves' ophthalmopathy.

Materials and methods: A retrospective review of radiotherapy delivered early in the active phase of Graves' ophthalmopathy was performed. All 47 cases had moderate-to-severe ophthalmopathy, and 30 cases had optic neuropathy. Variables examined included exophthalmos, color vision, and resistance to retropulsion. Statistical analyses comparing these variables at presentation and at 3 and 6 months after radiotherapy were performed. Subset analyses comparing responses of patients with symptoms lasting longer or less than 6 months were also performed.

Results: At 6 months after radiotherapy, there was improvement in exophthalmos in 74.5% of cases and improvement in retropulsion in 83.0%, and all cases of previous color deficiency improved. The mean improvement in exophthalmos was 1.38 mm, color vision was two plates, and retropulsion was 1 grade. On subset analyses, there was a trend toward greater improvement in patients treated earlier in the course of their symptoms.

Conclusions: Radiotherapy may play an important role in the treatment of Graves' ophthalmopathy, especially for patients with optic neuropathy. Early intervention (symptoms < 6 months) with radiotherapy may be the optimal timing for this treatment.

Publication types

  • Comparative Study

MeSH terms

  • Analysis of Variance
  • Female
  • Graves Disease / radiotherapy*
  • Humans
  • Male
  • Middle Aged
  • Optic Nerve Diseases / radiotherapy*
  • Retrospective Studies
  • Treatment Outcome